Trials / Terminated
TerminatedNCT01215266
Sorafenib in Urothelium Cancer of Bladder
Prospektiv, Randomisierte, Doppelblinde, Multizentrische Phase-II- Studie Zum Vergleich Der Wirksamkeit Einer Chemotherapie Mit Gemcitabin Plus Cisplatin Und Sorafenib (BAY 43-9006) Versus Gemcitabin Plus Cisplatin Und Plazebo in Der Therapie Des Lokal Fortgeschrittenen Bzw. Metastasierten Urothelkarzinoms AB 31/05 - RUTT 204 - SUSE
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Association of Urologic Oncology (AUO) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the use of Sorafenib additionally to gemcitabine and cisplatin in bladder cancer.
Detailed description
A controlled, double-blind, randomized study to evaluate the influence of Sorafenib in bladder cancer patients additionally to chemotherapy with gemcitabine and cisplatin compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | Day 3-21 2x2 800 mg(milligram) daily |
| DRUG | Placebo | Day 3-21 2x2 800 mg(milligram) daily |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-10-06
- Last updated
- 2011-09-08
Source: ClinicalTrials.gov record NCT01215266. Inclusion in this directory is not an endorsement.